Pyoderma gangrenosum is an ulcerating disorder of the skin with sterile neutrophilic inflammation that may be seen in up to 5% of patients with chronic ulceration of the legs. 1 Typically painful, it ...

Ulcerative pyoderma gangrenosum is a rare inflammatory disease with an incidence of 3–10 cases per million per year. 1 Consideration of the diagnosis is based on its classic morphological features: ...

Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMAProductive end-of-phase II meeting with FDA held for PG; dialogue ongoing related to Phase III program ...

Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) Trial size to be adapted upon interim analysis with planned total patient ...

A 39-year-old father is suffering from a horrifically painful skin disease that doctors can't cure or even definitively identify. The deadly sores are spreading across his body with every passing day.

PYODERMA gangrenosum is a rare skin condition that causes painful ulcers. It often develops due to over-activity of the immune system or following an injury or minor skin damage such as a needle ...

Send comments and news tips to [email protected]. Cite this: Edited by Deepa Varma. Pyoderma Gangrenosum in Pregnancy Often Misdiagnosed - Medscape - July 11, 2025.

Phase 3 pyoderma gangrenosum trial was halted after analysis of 30 patients showed no efficacy signal. InflaRx to prioritize INF904 with key data expected in chronic spontaneous urticaria and ...

InflaRx has initiated a phase 3 study of vilobelimab in patients with ulcerative pyoderma gangrenosum, the company announced in a press release. The multinational, randomized, double-blind ...

JENA, Germany, June 29, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement ...